Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tuesday broker round-up UPDATE

Tue, 29th Jul 2014 09:37

Abderdeen Asset Management: Berenberg cuts target price from 530p to 510p and maintains a buy recommendation.African Barrick Gold: Numis takes target price from 260p to 330p upgrading from hold to buy.Anglo American: Deutsche Bank increases target price from 1590p to 1650p and reiterates a hold recommendation. Investec raises target price from 1630p to 1760p and keeps a hold recommendation.APR Energy: Investec places its target price (prev.: 880p) under review, while keeping a hold recommendation.Barclays: Numis upgrades from add to buy with a target price of 280p.Brammer: Investec cuts target price from 450p to 435p, while upgrading from hold to buy.BSkyB: Westhouse Securities upgrades from neutral to add with a target price of 985p.BTG: Jefferies ups target price from 525p to 760p upgrading from hold to buy.Compass Group: Deutsche Bank raises target price from 1025p to 1105p and retains a buy recommendation.Daily Mail & General Trust: Credit Suisse reinstates with a target price of 1040p and an outperform rating.Drax Group: Goldman Sachs cuts target price from 1098p to 1052p retaining a strong buy recommendation.Gem Diamonds: FinnCap ups target price from 211p to 261p and maintains a buy recommendation. Westhouse Securities ups target price from 220p to 235p and reiterates its buy recommendation.GKN: Numis upgrades from add to buy with a target price of 435p.GlaxoSmithKline: Berenberg reduces target price from 1740p to 1520p, while leaving its hold recommendation unchanged.Hiscox: Deutsche Bank cuts target price from 658p to 646p staying with its sell recommendation. Canaccord Genuity shifts target price from 705p to 710p and reiterates a hold recommendation.HSBC Holdings: Deutsche Bank reduces target price from 640p to 593p and reiterates a hold recommendation.Hutchison China Meditech: Panmure Gordon raises target price from 950p to 1200p keeping a buy recommendation.Informa: Canaccord Genuity cuts target price from 535p to 515p staying with its hold recommendation.Jardine Lloyd Thompson: Numis cuts target price from 1190p to 1120p downgrading from add to hold.Ladbrokers: Deutsche Bank lowers target price from 177p to 165p and keeps a buy recommendation.Lancashire Holdings: Berenberg reduces target price from 720p to 666p keeping a hold recommendation.Pace: Numis reduces target price from 420p to 360p and reiterates a hold recommendation.Petra Diamonds: Beaufort upgrades to buy. Numis ups target price from 220p to 240p, while downgrading from buy to add.Provident Financial: Espirito Santo raises target price from 1808p to 2012p and retains a neutral rating.Reckitt Benckiser: Credit Suisse raises target price from 5200p to 5500p and maintains an outperform rating. Numis downgrades from add to hold with a target price of 5600p.Sinclair IS Pharma: Jefferies lowers target price from 50p to 45p staying with its buy recommendation.Spectris: Goldman Sachs reduces target price from 3050p to 2770p and keeps its strong buy recommendation. Credit Suisse reduces target price from 2560p to 2370p and leaves its outperform rating unaltered. Canaccord Genuity reduces target price from 2700p to 2400p and downgrades from buy to hold.Sweett Group: N+1 Singer cuts target price from 61p to 45p retaining a buy recommendation.Tesco: Shore Capital upgrades from sell to hold.Treatt: Investec moves target price from 150p to 160p reiterating a hold recommendation.Tullett Prebon: Numis places both its target price (prev.: 299p) and its reduce rating under review. Liberum Capital places its target price (prev.: 240p) under review with a sell recommendation. Canaccord Genuity places both its target price and recommendation under review.William Hill: Deutsche Bank cuts target price from 435p to 415p leaving its buy recommendation unchanged.Zoopla Property: Credit Suisse initiates with a target price of 290p and an outperform rating.7Digital: Investec initiates with a target price of 37p and a buy recommendation.
More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.